Publication

Lithium and Renal Impairment: A Review on a Still Hot Topic

Nielsen, R. E., Kessing, L. V., Nolen, W. A. & Licht, R. W., Sep-2018, In : Pharmacopsychiatry. 51, 5, p. 200-205 6 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Nielsen, R. E., Kessing, L. V., Nolen, W. A., & Licht, R. W. (2018). Lithium and Renal Impairment: A Review on a Still Hot Topic. Pharmacopsychiatry, 51(5), 200-205. https://doi.org/10.1055/s-0043-125393

Author

Nielsen, Rene Ernst ; Kessing, Lars Vedel ; Nolen, Willem A. ; Licht, Rasmus W. / Lithium and Renal Impairment : A Review on a Still Hot Topic. In: Pharmacopsychiatry. 2018 ; Vol. 51, No. 5. pp. 200-205.

Harvard

Nielsen, RE, Kessing, LV, Nolen, WA & Licht, RW 2018, 'Lithium and Renal Impairment: A Review on a Still Hot Topic', Pharmacopsychiatry, vol. 51, no. 5, pp. 200-205. https://doi.org/10.1055/s-0043-125393

Standard

Lithium and Renal Impairment : A Review on a Still Hot Topic. / Nielsen, Rene Ernst; Kessing, Lars Vedel; Nolen, Willem A.; Licht, Rasmus W.

In: Pharmacopsychiatry, Vol. 51, No. 5, 09.2018, p. 200-205.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Nielsen RE, Kessing LV, Nolen WA, Licht RW. Lithium and Renal Impairment: A Review on a Still Hot Topic. Pharmacopsychiatry. 2018 Sep;51(5):200-205. https://doi.org/10.1055/s-0043-125393


BibTeX

@article{30279182402643aa9b3dd106420cb97e,
title = "Lithium and Renal Impairment: A Review on a Still Hot Topic",
abstract = "Introduction Lithium is established as an effective treatment of mania, of depression in bipolar and unipolar disorder, and in maintenance treatment of these disorders. However, due to the necessity of monitoring and concerns about irreversible adverse effects, in particular renal impairment, after long-term use, lithium might be underutilized.Methods This study reviewed 6 large observational studies addressing the risk of impaired renal function associated with lithium treatment and methodological issues impacting interpretation of results.Results An increased risk of renal impairment associated with lithium treatment is suggested. This increased risk may, at least partly, be a result of surveillance bias. Additionally, the earliest studies pointed toward an increased risk of end-stage renal disease associated with lithium treatment, whereas the later and methodologically most sound studies do not.Discussion The improved renal outcome found in the more recent lithium studies may be a result of improved monitoring and focus on recommended serum levels (preferentially 0.6-0.8mmol/L) as compared to poorer renal outcome in studies with patients treated in the 1960s to 1980s.",
keywords = "lithium, renal impairment, epidemiology, adverse events, LONG-TERM LITHIUM, BIPOLAR DISORDER, KIDNEY DAMAGE, STRATEGIES, MANAGEMENT, SUICIDE, THERAPY, FAILURE, DISEASE, COHORT",
author = "Nielsen, {Rene Ernst} and Kessing, {Lars Vedel} and Nolen, {Willem A.} and Licht, {Rasmus W.}",
year = "2018",
month = "9",
doi = "10.1055/s-0043-125393",
language = "English",
volume = "51",
pages = "200--205",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "GEORG THIEME VERLAG KG",
number = "5",

}

RIS

TY - JOUR

T1 - Lithium and Renal Impairment

T2 - A Review on a Still Hot Topic

AU - Nielsen, Rene Ernst

AU - Kessing, Lars Vedel

AU - Nolen, Willem A.

AU - Licht, Rasmus W.

PY - 2018/9

Y1 - 2018/9

N2 - Introduction Lithium is established as an effective treatment of mania, of depression in bipolar and unipolar disorder, and in maintenance treatment of these disorders. However, due to the necessity of monitoring and concerns about irreversible adverse effects, in particular renal impairment, after long-term use, lithium might be underutilized.Methods This study reviewed 6 large observational studies addressing the risk of impaired renal function associated with lithium treatment and methodological issues impacting interpretation of results.Results An increased risk of renal impairment associated with lithium treatment is suggested. This increased risk may, at least partly, be a result of surveillance bias. Additionally, the earliest studies pointed toward an increased risk of end-stage renal disease associated with lithium treatment, whereas the later and methodologically most sound studies do not.Discussion The improved renal outcome found in the more recent lithium studies may be a result of improved monitoring and focus on recommended serum levels (preferentially 0.6-0.8mmol/L) as compared to poorer renal outcome in studies with patients treated in the 1960s to 1980s.

AB - Introduction Lithium is established as an effective treatment of mania, of depression in bipolar and unipolar disorder, and in maintenance treatment of these disorders. However, due to the necessity of monitoring and concerns about irreversible adverse effects, in particular renal impairment, after long-term use, lithium might be underutilized.Methods This study reviewed 6 large observational studies addressing the risk of impaired renal function associated with lithium treatment and methodological issues impacting interpretation of results.Results An increased risk of renal impairment associated with lithium treatment is suggested. This increased risk may, at least partly, be a result of surveillance bias. Additionally, the earliest studies pointed toward an increased risk of end-stage renal disease associated with lithium treatment, whereas the later and methodologically most sound studies do not.Discussion The improved renal outcome found in the more recent lithium studies may be a result of improved monitoring and focus on recommended serum levels (preferentially 0.6-0.8mmol/L) as compared to poorer renal outcome in studies with patients treated in the 1960s to 1980s.

KW - lithium

KW - renal impairment

KW - epidemiology

KW - adverse events

KW - LONG-TERM LITHIUM

KW - BIPOLAR DISORDER

KW - KIDNEY DAMAGE

KW - STRATEGIES

KW - MANAGEMENT

KW - SUICIDE

KW - THERAPY

KW - FAILURE

KW - DISEASE

KW - COHORT

U2 - 10.1055/s-0043-125393

DO - 10.1055/s-0043-125393

M3 - Review article

VL - 51

SP - 200

EP - 205

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 5

ER -

ID: 64818395